Head and Neck Squamous Cell Carcinoma HNSCCPhase 1NCT07227168
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
A Phase 1 study testing STRO-004 and Pembrolizumab in people with Head and Neck Squamous Cell Carcinoma HNSCC and Non-Small Cell Lung Cancer NSCLC, run by Sutro Biopharma, Inc. at 9 sites in United States.
Trial summary
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer
- What is being tested?
- STRO-004 and Pembrolizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 9 sitesUnited States
- Study dates
- 7 Nov 2025to Apr 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically or cytologically documented metastatic or locally advanced solid tumors including: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Esophageal/Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Cervical Cancer, Endometrial Cancer, and Urothelial Carcinoma
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
- Received all appropriate systemic therapies that are locally available for which they are eligible. For Parts 1A and 1C, there is no limit on the number of prior therapies. For Part 1B only, up to 3 prior therapies are allowed, except for NSCLC participants with genomic alterations, who may have up to 4 prior therapies
- Availability of tumor tissue
- Measurable disease per RECIST 1.1
- Adequate organ function
- Participants receiving anticoagulants must be on a stable dose
Who cannot join
- Eye disorders
- Untreated brain metastases
- Pre-existing clinically significant ocular disorders, active interstitial lung disease, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition
- Previous solid organ or bone marrow transplantation
- Concurrent participation in another therapeutic treatment trial
Trial locations and contacts
9 sites in 1 country. Contact the study team or a site near you to ask about taking part.
9 sites in 1 country
United States9 sites, 9 recruiting
- Recruiting
NEXT Austin
Austin, Texas, 78758
Kayla Grossi, 737-610-5200, kgrossi@nextoncology.com
China Whitwer, 737-610-5200, cwhitwer@nextoncology.com
- Recruiting
Mass General Cancer Center
Boston, Massachusetts, 02114
Leon Pappas, MD, 617-643-5470, lpappas3@mgb.org
Julia Rapisadra, 617-643-5470, jrapisarda@mgh.harvard.edu
- Recruiting
SCRI Denver
Denver, Colorado, 80218
Jessica Ellis, 720-754-2610, Jessica.Ellis@SarahCannon.com
Julia Etchart, 720-754-2610, Julia.Etchart@SarahCannon.com
- Recruiting
NEXT Virginia
Fairfax, Virginia, 22031
Kayla Grossi, 703-783-4510, kgrossi@nextoncology.com
Allison Delgado, 703-783-4510, adelgado@nextoncology.com
- Recruiting
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
New York, New York, 10029
Jordan Cuevas, 212-824-7945, Jordan.Cuevas@mssm.edu
Gabriela Fazilov, 212-824-7945, gabriela.fazilov@mssm.edu
- Recruiting
NEXT San Antonio
San Antonio, Texas, 78229
Kayla Grossi, 210-580-9511, kgrossi@nextoncology.com
China Whitwer, 210-580-9511, cwhitwer@nextoncology.com
- Recruiting
UC San Diego Moores Cancer Center
San Diego, California, 92037
Gloria Neilson, 858-822-5677, gneilson@health.ucsd.edu
Kathy Velasco, M.D., 858-822-5677, kcvelasco@health.ucsd.edu
- Recruiting
SCRI FCS Sarasota
Sarasota, Florida, 34232
Sarah Gwirtz, 941-377-9993 ext. option 1, Sarah.Gwirtz@flcancer.com
Heather Schmitz, 941-377-9993 ext. option 1, heather.schmitz@flcancer.com
- Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
Matthew Caffet, 202-687-8632, mc2731@georgetown.edu
Chul Kim, M.D., (202) 444-2223, chul.kim@gunet.georgetown.edu
About this study
Official title: A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts:
- Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF).
- Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity.
- Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Being tested
- STRO-004, Pembrolizumab
- Keywords
- Tissue Factor (TF), STRO-004, Antibody Drug Conjugate, ADC
- Medical subject headings
- Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
STRO-004Drug
IV Infusion
PembrolizumabDrug
IV Infusion
| Study group | Role | What they receive |
|---|---|---|
| Part 1A STRO-004 Monotherapy | Experimental | Not described Receives: Drug: STRO-004 |
| Part 1B STRO-004 Monotherapy | Experimental | Not described Receives: Drug: STRO-004 |
| Part 1C STRO-004 in Combination with Pembrolizumab | Experimental | Not described Receives: Drug: STRO-004; Drug: Pembrolizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Part 1A: Number of participants with Dose-limiting Toxicities (DLTs)
Measured: Up to Day 21
Part 1A, 1B: Percentage of participants with Treatment-Emergent Adverse Events (TEAEs), with severity determined according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading scale
Measured: Up to 12 Months
Part 1A, 1B, 1C: Percentage of participants with clinical laboratory abnormalities, with severity determined according to the CTCAE v5.0 grading scale
Measured: Up to 12 months
Part 1B: Objective Response Rate (ORR)
Best response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)
Measured: Up to 12 months
Part 1B: Disease control rate (DCR)
The proportion of participants with best response of CR, PR or Stable Disease (SD) per RECIST V1.1
Measured: Up to 12 months
Part 1B: Duration of Response (DOR)
Time from first occurrence of objective response to the time of Progressive Disease (PD) according to RECIST v1.1 or death from any cause, whichever comes first
Measured: Up to 12 months
Part 1B: Progression-Free Survival (PFS)
Time from first dose to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first
Measured: Up to 12 months
Part 1B: 12-month survival rate
Percentage of participants alive 12 months after first dose of study treatment
Measured: 12 months
Part 1C: Percentage of participants with TEAEs, with severity determined according to the CTCAE v5.0 grading scale
Measured: Up to 12 months
Secondary outcomes (7)
Part 1A, 1B, 1C: Plasma concentrations of STRO-004 and its metabolites at specified timepoints
Measured: Up to 12 months
Part 1A, 1B, 1C: Immunogenicity
As measured by circulating antidrug antibody (ADA) over time
Measured: Up to 12 months
Part 1A: Objective Response Rate (ORR)
Up to 12 months
Measured: Best response of CR or PR per RECIST V1.1
Part 1A, 1C: Disease Control Rate (DCR)
Proportion of participants with best response of CR, PR or SD per RECIST V1.1
Measured: Up to 12 months
Part 1A, 1C: Duration of Response (DOR)
Time from first occurrence of objective response to the time of PD according to RECIST v1.1 or death from any cause, whichever comes first
Measured: Up to 12 months
Part 1A,1C: Progression-Free Survival (PFS)
Time from first dose to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first
Measured: Up to 12 months
Part 1A,1C: 12-month survival rate
Proportion of participants alive 12 months after the date of first dose of study treatment
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2025
- Study start7 Nov 2025
- Primary completionDec 2027 (estimated)
- Study completionApr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Head and Neck Squamous Cell Carcinoma HNSCCStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sutro Biopharma, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07227168
- Sponsor's protocol ID
- STRO-004-ST1
- Status last verified
- Aug 2026
- First submitted
- 7 Nov 2025
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors
- ClinicalTrials.gov ID
- NCT07227168
- Acronym / sponsor ID
- STRO-004-ST1
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Keywords
- Tissue Factor (TF), STRO-004, Antibody Drug Conjugate, ADC
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Sutro Biopharma, Inc.Industry (pharma, biotech, devices)
- Study start
- 7 Nov 2025 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Apr 2028 (estimated)
- First posted
- 12 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts:
- Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF).
- Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity.
- Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Part 1A STRO-004 Monotherapy | Experimental | Drug: STRO-004 |
| Part 1B STRO-004 Monotherapy | Experimental | Drug: STRO-004 |
| Part 1C STRO-004 in Combination with Pembrolizumab | Experimental | Drug: STRO-004, Drug: Pembrolizumab |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Histologically or cytologically documented metastatic or locally advanced solid tumors including: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Esophageal/Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Cervical Cancer, Endometrial Cancer, and Urothelial Carcinoma
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
- Received all appropriate systemic therapies that are locally available for which they are eligible. For Parts 1A and 1C, there is no limit on the number of prior therapies. For Part 1B only, up to 3 prior therapies are allowed, except for NSCLC participants with genomic alterations, who may have up to 4 prior therapies
- Availability of tumor tissue
Key exclusion criteria (5 listed)
- Eye disorders
- Untreated brain metastases
- Pre-existing clinically significant ocular disorders, active interstitial lung disease, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition
- Previous solid organ or bone marrow transplantation
- Concurrent participation in another therapeutic treatment trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| STRO-004IV Infusion | Drug | Part 1A STRO-004 Monotherapy, Part 1B STRO-004 Monotherapy, Part 1C STRO-004 in Combination with Pembrolizumab |
| PembrolizumabIV Infusion | Drug | Part 1C STRO-004 in Combination with Pembrolizumab |
Primary outcome
Part 1A: Number of participants with Dose-limiting Toxicities (DLTs)
Time frame: Up to Day 21
Part 1A, 1B: Percentage of participants with Treatment-Emergent Adverse Events (TEAEs), with severity determined according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading scale
Time frame: Up to 12 Months
Part 1A, 1B, 1C: Percentage of participants with clinical laboratory abnormalities, with severity determined according to the CTCAE v5.0 grading scale
Time frame: Up to 12 months
Part 1B: Objective Response Rate (ORR)
Time frame: Up to 12 months
Best response of Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)
Part 1B: Disease control rate (DCR)
Time frame: Up to 12 months
The proportion of participants with best response of CR, PR or Stable Disease (SD) per RECIST V1.1
Part 1B: Duration of Response (DOR)
Time frame: Up to 12 months
Time from first occurrence of objective response to the time of Progressive Disease (PD) according to RECIST v1.1 or death from any cause, whichever comes first
Part 1B: Progression-Free Survival (PFS)
Time frame: Up to 12 months
Time from first dose to the first occurrence of PD according to RECIST v1.1 or death from any cause, whichever comes first
Part 1B: 12-month survival rate
Time frame: 12 months
Percentage of participants alive 12 months after first dose of study treatment
Part 1C: Percentage of participants with TEAEs, with severity determined according to the CTCAE v5.0 grading scale
Time frame: Up to 12 months
7 secondary outcomes
Part 1A, 1B, 1C: Plasma concentrations of STRO-004 and its metabolites at specified timepoints
Time frame: Up to 12 months
Part 1A, 1B, 1C: Immunogenicity
Time frame: Up to 12 months
Part 1A: Objective Response Rate (ORR)
Time frame: Best response of CR or PR per RECIST V1.1
Part 1A, 1C: Disease Control Rate (DCR)
Time frame: Up to 12 months
Part 1A, 1C: Duration of Response (DOR)
Time frame: Up to 12 months
Part 1A,1C: Progression-Free Survival (PFS)
Time frame: Up to 12 months
Part 1A,1C: 12-month survival rate
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
Related trials for Head and Neck Squamous Cell Carcinoma HNSCC
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
RecruitingPhase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing STRO-004 and Pembrolizumab in people with Head and Neck Squamous Cell Carcinoma HNSCC and Non-Small Cell Lung Cancer NSCLC, run by Sutro Biopharma, Inc. at 9 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sutro Clinical Development (650-801-6416, ClinicalTrials@sutrobio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) (time frame: Up to Day 21). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.